Trial Profile
TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Jun 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms TYGRIS-ROW
- Sponsors Biogen
- 12 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 16 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 May 2009 Planned end date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.